# Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026 - Egetis Therapeutics
Canonical URL: https://biopharmsignal.com/news/EGTX/egetis-therapeutics-to-participate-in-leading-international-medical-conferences--5e606850
Ticker: EGTX
Company: Egetis
Source: Egetis
Published: 2026-07-09 00:02 EST
Original Source URL: https://www.egetis.com/mfn_news/
## Summary

Stockholm, May 7, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) today announced that the Company is planning to participate in several upcoming medical conferences in 2026, including: American Academy of Cerebral Palsy and Developmental Medicine (AACPDM)Philadelphia, PA, USA British Thyroid Association (BTA)London, UK Child Neurology Society (CNS)Montreal, Canada European Society […]

## Article Body
Stockholm, May 7, 2026. Egetis Therapeutics AB (publ) (“Egetis” or the “Company”) (Nasdaq Stockholm: EGTX) today announced that the Company is planning to participate in several upcoming medical conferences in 2026, including:

American Academy of Cerebral Palsy and Developmental Medicine (AACPDM) Philadelphia, PA, USA

British Thyroid Association (BTA) London, UK

Child Neurology Society (CNS) Montreal, Canada

European Society for Paediatric Endocrinology (ESPE) Marseille, France

European Thyroid Association (ETA) Porto, Portugal

German Pediatrics Conference (DGKJ) Berlin, Germany

German Society for Neuropediatrics (GNP) Linz, Austria

German Society for Pediatric Endocrinology (JA-PED) Berlin, Germany

Société Française de Pédiatrie (SFP) Paris, France

Society for Developmental and Behavioral Pediatrics (SDBP) New Orleans, LA, USA

Society for the Study of Inborn Errors of Metabolism (SSIEM) Helsinki, Finland

Spanish Society of Paediatric Endocrinology Foundation (FSEEP) Barcelona, Spain

Nicklas Westerholm, CEO, commented: “Our participation in leading international conferences throughout 2026 reflects our continued focus and commitment on raising awareness of MCT8 deficiency and contributing to the exchange of knowledge around this devastating rare disease.”
## Recent Company News
- 2026-07-09 15:46 EST — [Exercise of options under employee stock option program and notification of insider trading - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/exercise-of-options-under-employee-stock-option-program-and-notification-of-insi-e6812443) — Source: Egetis
- 2026-07-09 00:02 EST — [Egetis Therapeutics to Participate in Leading International Medical Conferences in 2026 - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-therapeutics-to-participate-in-leading-international-medical-conferences--5e606850) — Source: Egetis
- 2026-07-09 00:01 EST — [Egetis to present healthcare resource drivers and cost in MCT8 deficiency at ISPOR 2026 - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-to-present-healthcare-resource-drivers-and-cost-in-mct8-deficiency-at-isp-c2a98b15) — Source: Egetis
- 2026-07-09 00:01 EST — [Egetis Therapeutics Announces National Re-Airing of Behind the Mystery Episode on Lifetime Spotlighting MCT8 Deficiency - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/egetis-therapeutics-announces-national-re-airing-of-behind-the-mystery-episode-o-f519aa28) — Source: Egetis
- 2026-05-29 00:00 EST — [Change in the number of shares and votes in Egetis Therapeutics - Egetis Therapeutics](https://biopharmsignal.com/news/EGTX/change-in-the-number-of-shares-and-votes-in-egetis-therapeutics-egetis-therapeut-efcee0d2) — Source: Egetis
## Related News
- 2026-07-21 12:00 EST — MOR — [Novartis delivered sales growth in Q2 and further advanced the pipeline; Full-year guidance reaffirmed](https://biopharmsignal.com/news/MOR/novartis-delivered-sales-growth-in-q2-and-further-advanced-the-pipeline-full-yea-63a32b47)
- 2026-07-21 10:28 EST — GSK — [ViiV Healthcare to present phase IIIb data comparing Dovato with Biktarvy in treatment-naïve adults alongside INSTI-powered long-acting injectable innovation at AIDS 2026](https://biopharmsignal.com/news/GSK/viiv-healthcare-to-present-phase-iiib-data-comparing-dovato-with-biktarvy-in-tre-1ff3f640)
- 2026-07-20 20:05 EST — RANI — [Rani Therapeutics Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)](https://biopharmsignal.com/news/RANI/rani-therapeutics-reports-inducement-grant-under-nasdaq-listing-rule-5635-c-4-ec56b3b0)
- 2026-07-20 14:53 EST — IPHA — [Innate Pharma announces Completion of Enrollment in Phase 1 Dose Escalation Study of IPH4502, a Novel Nectin-4 Exatecan Antibody-Drug Conjugate (ADC)](https://biopharmsignal.com/news/IPHA/innate-pharma-announces-completion-of-enrollment-in-phase-1-dose-escalation-stud-0778493f)
- 2026-07-20 13:05 EST — ACAD — [Acadia Pharmaceuticals Receives FDA Fast Track Designation for Remlifanserin in Alzheimer's Disease Psychosis](https://biopharmsignal.com/news/ACAD/acadia-pharmaceuticals-receives-fda-fast-track-designation-for-remlifanserin-in--f36b622c)